European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

Scale-up of an Advanced Manufacturing process to produce a Pharmaceutical product Application (SAMPA).

Obiettivo

Sublimity Therapeutics has developed an innovative product, ST-0529, to treat patients with moderate-severe Ulcerative Colitis, a disease that affects 1 million patients in Europe. ST-0529 is enabled using Sublimity Therapeutics ’s proprietary SmPill® nanoemulsion-based technology to target a known and powerful drug, Cyclosporine, directly to inflamed colons. In Phase II human studies, ST-0529 was proven to be effective and safe. ST-0529, an oral product, will compete with injected, expensive drugs that have a risk of serious side effects.

Successful development and commercialisation of ST-0529 will pivot on development of a stable ST-0529 product and a positive outcome of the clinical trials.
Overall, the project will involve leading EU-based specialist SME, technology and equipment suppliers as well as a number of knowledge providers. The budget is €1.6M and will be completed in 58 months.
Successful completion of this project will retain and enhance intellectual property and know-how in Sublimity Therapeutics, increase long term high skill jobs. In parallel, the project will unlock the value inherent not only of ST-0529, but also the underlying SmPill® technology platform. Furthermore, the project will increase the probability of overall company success and increase significantly the NPV to more than €500M.

Invito a presentare proposte

H2020-SMEInst-2014-2015

Vedi altri progetti per questo bando

Bando secondario

H2020-SMEINST-2-2014

Meccanismo di finanziamento

SME-2 - SME instrument phase 2

Coordinatore

SUBLIMITY THERAPEUTICS LIMITED
Contribution nette de l'UE
€ 1 600 000,00
Indirizzo
INVENT CENTRE DUBLIN CITY UNIVERSITY
9 DUBLIN
Irlanda

Mostra sulla mappa

PMI

L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.

Regione
Ireland Eastern and Midland Dublin
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 2 307 500,00